FY2025 EPS Forecast for Hims & Hers Health Lifted by Analyst

Hims & Hers Health, Inc. (NYSE:HIMS) – Stock analysts at Seaport Res Ptn increased their FY2025 earnings per share (EPS) estimates for shares of Hims & Hers Health in a note issued to investors on Monday, February 24th. Seaport Res Ptn analyst A. Kessler now anticipates that the company will post earnings of $0.64 per share for the year, up from their prior forecast of $0.51. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.29 per share. Seaport Res Ptn also issued estimates for Hims & Hers Health’s FY2026 earnings at $1.10 EPS.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. The business had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%.

Several other analysts have also recently issued reports on the company. Needham & Company LLC increased their target price on Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a research report on Tuesday. BTIG Research started coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price objective for the company. Leerink Partners boosted their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a report on Tuesday. Truist Financial raised their target price on shares of Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a research note on Wednesday. Finally, Bank of America increased their price objective on shares of Hims & Hers Health from $18.00 to $21.00 and gave the company an “underperform” rating in a report on Thursday, February 20th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $35.71.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $41.30 on Thursday. Hims & Hers Health has a fifty-two week low of $11.20 and a fifty-two week high of $72.98. The company has a market capitalization of $9.02 billion, a P/E ratio of 93.85 and a beta of 1.35. The company has a fifty day moving average of $36.19 and a 200 day moving average of $26.46.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of Hims & Hers Health by 11.1% in the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock worth $489,817,000 after acquiring an additional 2,020,722 shares in the last quarter. Farallon Capital Management LLC boosted its position in Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock valued at $202,556,000 after buying an additional 8,364,000 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Hims & Hers Health by 29.0% in the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock valued at $168,079,000 after acquiring an additional 1,562,302 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its position in Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock worth $152,436,000 after purchasing an additional 4,145,305 shares during the period. Finally, State Street Corp increased its holdings in shares of Hims & Hers Health by 4.7% during the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company’s stock valued at $85,221,000 after purchasing an additional 206,078 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Transactions at Hims & Hers Health

In other news, insider Michael Chi sold 2,054 shares of Hims & Hers Health stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $33.56, for a total transaction of $68,932.24. Following the completion of the sale, the insider now owns 184,947 shares of the company’s stock, valued at approximately $6,206,821.32. The trade was a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Andrew Dudum sold 33,513 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $33.38, for a total value of $1,118,663.94. Following the completion of the transaction, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $1,118,296.76. This trade represents a 50.01 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,097,578 shares of company stock worth $38,080,320. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.